{"id":"leuprolide-acetate-formulation-a","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Hot flashes"},{"rate":"10–20","effect":"Injection site reaction"},{"rate":"20–40","effect":"Decreased libido"},{"rate":"20–40","effect":"Erectile dysfunction"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"5–10","effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in gonadotropin release followed by sustained suppression of LH and FSH through receptor desensitization. This results in profound suppression of sex hormone production, making it effective for hormone-dependent conditions such as prostate cancer, endometriosis, and uterine fibroids.","oneSentence":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:46.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids (leiomyomata)"},{"name":"Central precocious puberty"}]},"trialDetails":[{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT05493709","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2023-06-02","conditions":"Puberty; Precocious, Central","enrollment":93},{"nctId":"NCT03695237","phase":"PHASE3","title":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-24","conditions":"Central Precocious Puberty (CPP)","enrollment":45},{"nctId":"NCT03261999","phase":"PHASE3","title":"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2017-09-26","conditions":"Prostatic Neoplasms","enrollment":144},{"nctId":"NCT03093272","phase":"PHASE2","title":"A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-06-23","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT00254397","phase":"PHASE2","title":"Melanoma Vaccine With Peptides and Leuprolide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-11","conditions":"Melanoma","enrollment":98},{"nctId":"NCT02234115","phase":"PHASE3","title":"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2014-08","conditions":"Prostatic Neoplasms","enrollment":137},{"nctId":"NCT01415960","phase":"PHASE3","title":"Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer","status":"COMPLETED","sponsor":"GP-Pharm","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":163},{"nctId":"NCT00667446","phase":"PHASE3","title":"Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-12","conditions":"Precocious, Leuprolide Acetate, Luteinizing Hormone (LH)","enrollment":72},{"nctId":"NCT01161563","phase":"PHASE4","title":"Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2010-07","conditions":"Prostate Cancer","enrollment":118},{"nctId":"NCT01132404","phase":"PHASE1, PHASE2","title":"Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2010-11","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":9},{"nctId":"NCT00635817","phase":"PHASE3","title":"A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-06","conditions":"Puberty, Precocious","enrollment":84},{"nctId":"NCT00626431","phase":"PHASE3","title":"A Study of Leuprolide to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":310},{"nctId":"NCT00630799","phase":"PHASE3","title":"Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients","status":"TERMINATED","sponsor":"GP-Pharm","startDate":"2008-05","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT00776074","phase":"PHASE2","title":"A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-06","conditions":"Uterine Fibroids","enrollment":80},{"nctId":"NCT00161421","phase":"PHASE2","title":"Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-03","conditions":"Contraception, Hypogonadism","enrollment":18},{"nctId":"NCT00056654","phase":"NA","title":"Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-03","conditions":"Prostatic Neoplasms","enrollment":164},{"nctId":"NCT00128531","phase":"PHASE3","title":"Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer","status":"COMPLETED","sponsor":"GP-Pharm","startDate":"2005-09","conditions":"Prostate Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"],"phase":"phase_3","status":"active","brandName":"Leuprolide acetate - Formulation A","genericName":"Leuprolide acetate - Formulation A","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids (leiomyomata).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}